ANN ARBOR, Mich., Sept. 23 /PRNewswire-USNewswire/ -- Compendia Bioscience, Inc. today announced the release of Oncomine Research Edition version 4.2, a significant product upgrade for the academic and non-profit communities. Since its inception, Compendia has been fully committed to supporting academic and non-profit cancer research efforts worldwide. This new version of Oncomine features a completely redesigned user-interface, improved search and filter capabilities, and several other new features designed to make gene discovery and validation simpler and more efficient.
Cancer researchers have made Oncomine the industry standard with over 12,000 academic users. These researchers use Oncomine to discover new genes, evaluate pathways and better understand specific cancer types resulting in the publication of more than 200 peer reviewed journal articles. Oncomine has led to several major cancer research discoveries such as the recent publication of AGTR1 overexpression and sensitivity to losartan in breast cancer (Proc Natl Acad Sci U S A. 2009 Jun 1).
"We are really pleased to release this exciting new version of Oncomine to the academic research community," said Compendia's Co-Founder and CEO Dan Rhodes, Ph.D. "We are confident that Oncomine 4 will continue to accelerate cancer research and lead to important new discoveries."
New Features and Capabilities in Oncomine 4 Research Edition
While improved user experience was the driving force in Oncomine 4 Research Edition, the entire Oncomine database was scrutinized in an effort to standardize and catalog all data points. In creating the Compendia Ontology, 300,000+ sample facts across 30,000+ samples were individually reviewed and terms normalized.
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com
Oncomine combines a rapidly growing compendium of 39,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm
|SOURCE Compendia Bioscience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved